Cell. 2021 Oct 14;184(21):5293-5296. doi: 10.1016/j.cell.2021.08.006. Epub 2021 Sep 24.
The highly effective and safe mRNA-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines draw on decades of painstaking research to overcome the many hurdles for delivering, expressing, and avoiding toxicity of therapeutic mRNA. Cell editor Nicole Neuman talked with Dr. Katalin Karikó and Dr. Drew Weissman, recipients of the 2021 Lasker∼DeBakey Clinical Medical Research Award, to learn more about their quest to develop mRNA-based therapeutics, which led them to the crucial discovery that modification of mRNA could prevent toxicity and increase expression. This conversation has been adapted for print below, with editing for clarity, accuracy, and length.
高效且安全的基于信使 RNA 的严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 疫苗利用了数十年的艰苦研究，以克服传递、表达和避免治疗性信使 RNA 毒性的诸多障碍。细胞编辑妮可·纽曼（Nicole Neuman）博士与 Katalin Karikó 和 Drew Weissman 博士进行了交谈，他们是 2021 年拉斯克-德贝基临床医学研究奖的获得者，以了解更多关于他们开发基于信使 RNA 的治疗方法的研究，这使他们做出了一个重要发现，即信使 RNA 的修饰可以防止毒性并提高表达。下面是这次对话的改编版，经过了编辑以确保清晰、准确和篇幅。
